The protozoan inositol phosphorylceramide synthase : a novel drug target that defines a new class of sphingolipid synthase. by Denny,  P. W. et al.
Durham Research Online
Deposited in DRO:
13 January 2014
Version of attached ﬁle:
Accepted Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Denny, P. W. and Shams-Eldin, H. and Price, H. P. and Smith, D. F. and Schwarz, R. T. (2006) 'The
protozoan inositol phosphorylceramide synthase : a novel drug target that deﬁnes a new class of sphingolipid
synthase.', Journal of biological chemistry., 281 (38). pp. 28200-28209.
Further information on publisher's website:
http://dx.doi.org/10.1074/jbc.M600796200
Publisher's copyright statement:
This research was originally published in Journal of biological chemistry. Denny, P. W. and Shams-Eldin, H. and Price,
H. P. and Smith, D. F. and Schwarz, R. T. (2006) 'The protozoan inositol phosphorylceramide synthase : a novel drug
target that deﬁnes a new class of sphingolipid synthase.', Journal of biological chemistry., 281 (38). pp. 28200-28209 c©
the American Society for Biochemistry and Molecular Biology"
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro-test.dur.ac.uk
 1 
THE PROTOZOAN INOSITOL PHOSPHORYLCERAMIDE SYNTHASE: 
A NOVEL DRUG TARGET WHICH DEFINES A  
NEW CLASS OF SPHINGOLIPID SYNTHASE 
 
Paul W. Denny*, Hosam Shams-Eldin1, Helen. P. Price2,  
Deborah F. Smith2, Ralph T. Schwarz1 
 
Centre for Infectious Diseases, Wolfson Research Institute, Durham University, 
Queen's Campus, Stockton-on-Tees, TS17 6BH, UK 
1Institute for Virology, Medical Center of Hygiene & Medical Microbiology,  
Philipps-University Marburg, Hans-Meerwein-Strasse, 35043 Marburg, Germany; and   
Unité de Glycobiologie Structurale et Fonctionnelle, UMR CNRS/USTL n° 8576 - IFR 118,  
Université des Sciences et Technologies de Lille, 59655 Villeneuve D'Ascq cedex – France. 
2Immunology and Infection Unit, Department of Biology, University of York, Heslington, York, YO10 5YW, UK. 
Running title: Protozoan IPC synthase 
*Address correspondence to: Dr Paul W. Denny, Centre for Infectious Diseases, Wolfson Research Institute 
Durham University, Queen's Campus, Stockton-on-Tees, TS17 6BH, UK.  
Tel. +44 (0)191 334 0319; Email: mailto:p.w.denny@durham.ac.uk 
  
 
 Sphingolipids are ubiquitous and essential 
components of eukaryotic membranes, particularly 
the plasma membrane. The biosynthetic pathway 
for the formation of these lipid species is conserved 
up to the formation of sphinganine. However, a 
divergence is apparent in the synthesis of complex 
sphingolipids. In animal cells, ceramide is a 
substrate for sphingomyelin (SM) production via 
the enzyme SM synthase. In contrast, fungi utilise 
phytoceramide in the synthesis of inositol 
phosphorylceramide (IPC) catalysed by IPC 
synthase. Due to the absence of a mammalian 
equivalent, this essential enzyme represents an 
attractive target for anti-fungal compounds. In 
common with the fungi, the kinetoplastid protozoa 
(and higher plants) synthesize IPC rather than SM. 
However, orthologues of the gene believed to encode 
the fungal IPC synthase (AUR1) are not readily 
identified in the complete genome databases of these 
species. By utilising bioinformatic and functional 
genetic approaches, we have isolated a functional 
orthologue of AUR1 in the kinetoplastids, causative 
agents of a range of important human diseases. 
Expression of this gene in a mammalian cell line led 
to the synthesis of an IPC-like species strongly 
indicating that IPC synthase activity is 
reconstituted. Furthermore the gene product can be 
specifically inhibited by an anti-fungal targeting 
IPC synthase. We propose that the kinetoplastid 
AUR1 functional orthologue encodes an enzyme 
which defines a new class of protozoan sphingolipid 
synthase. The identification and characterisation of 
the protozoan IPC synthase, an enzyme with no 
mammalian equivalent, will raise the possibility of 
developing anti-protozoal drugs with minimal toxic 
side-affects. 
 
INTRODUCTION 
 
 The evolutionarily divergent, insect vector borne 
protozoan parasites of the order Kinetoplastidae cause 
a range of human diseases, including the leishmaniases 
(a broad spectrum of infections caused by Leishmania 
species), Chagas’ disease (Trypanosoma cruzi) and 
African sleeping sickness (T. brucei). These infections 
are of increasing prevalence in developing countries 
where mortality is often affected by poor access to 
health care. Many of the drugs available to treat these 
diseases are expensive, difficult to administer or toxic 
and no effective vaccines are available (1,2). These 
facts make the discovery of new anti-kinetoplastid 
therapeutic targets and compounds of paramount 
importance (http://www.who.int/tdr). 
 Sphingolipids are amphipathic lipids that have a 
sphingoside backbone with a long-chain fatty acid and 
a polar alcohol as attachments. Ceramide is an 
unmodified sphingolipid that functions as a key player 
in cell signalling and as a precurser of complex 
sphingolipids which are major components of the outer 
leaflet of eukaryotic plasma membranes thought to be 
involved, together with sterols, in the formation of 
micro-domains known as lipid rafts (3). These rafts 
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have been proposed to function in a diverse array of 
processes from the polarised trafficking of lipid-
modified proteins (4), to the assembly and activation of 
signal transduction complexes (5,6). Unlike 
mammalian cells, which synthesize sphingomyelin 
(SM), the primary complex sphingolipid species in 
Leishmania spp. and Trypanosoma spp. is inositol 
phosphorylceramide (IPC) (7). Similarly, in fungi and 
plants, IPC and its glycosylated derivatives are 
abundant complex sphingolipid species (7,8) (see 
figure 1). IPC is produced by the transfer of a 
phosphorylinositol head group from 
phosphatidylinositol (PI) to ceramide, a process 
catalysed by IPC synthase (9). In the fungi, IPC 
synthase or a subunit of this enzyme is believed to be 
encoded by the AUR1 gene that was first identified in 
Saccharomyces cerevisiae and subsequently in several 
pathogenic species (10). As in the protozoan parasites, 
the search for specific drug targets in the pathogenic 
fungi is hampered by the conservation of biochemical 
processes between the eukaryotic microbe and its 
eukaryotic host. Consequently, as for anti-protozoan 
therapies, many of the available anti-fungals exhibit 
toxic side-effects. IPC synthase has no functional 
equivalent in mammals. As such this enzyme activity 
has been established as a target for the development of 
anti-fungal compounds (11), a number of which have 
been characterized (12). 
 No homologue of the fungal AUR1 gene has been 
found in either the complete protozoan or plant genome 
sequence databases. However, given the efficacy of 
known yeast inhibitors against the plant IPC synthase 
activity, it appears likely that the enzyme is conserved 
in plants at least (13). The biosynthesis of sphingoid 
base and ceramide, precursors of complex 
sphingolipids, are non-essential for Leishmania 
pathogenesis in an animal model system (14). 
However, it is known that intra-macrophage 
amastigotes possess an active IPC synthase presumably 
utilising precursors from alternative sources (15). 
Indeed it has been shown that L. donovani stimulates 
host macrophages to up-regulate the production of 
ceramide, a precursor of IPC and a substrate of IPC 
synthase (see figure 1) (16). Moreover, sphingolipid 
synthesis is essential for replication of pathogenic 
bloodstream form T. brucei (Denny et al. in 
preparation). IPC synthase activity has been 
characterised in T. cruzi (17) where it has been 
suggested that IPC synthesis is important for infectivity 
(18). In this context, it should be noted that IPC 
synthase is believed to play a pivotal role in the 
pathogenesis of the fungus Cryptococcus neoformans 
which, like Leishmania spp. and T. cruzi, resides in an 
acidic, macrophage phagolysosome. Genetically 
induced down-regulation of the C. neoformans AUR1 
confers an in vivo growth defect through a pH-
dependent mechanism (19).  
 Here we describe the identification and 
characterisation of an AUR1 functional orthologue in 
Leishmania major, the putative protozoan IPC synthase 
(LmIPCS).  It is proposed that this protein defines a 
new class of eukaryotic sphingolipid synthases. In 
addition, the development of an ex vivo assay system 
has allowed the identification of an inhibitor with 
specific activity against LmIPCS. This work will 
facilitate the rational development of inhibitors against 
a protozoan enzyme with no mammalian equivalent, 
leading to the prospect of anti-protozoal compounds 
with minimal toxic side effects. 
 
EXPERIMENTAL PROCEDURES 
 
Selection and cloning of a candidate AUR1 orthologue 
- Candidate genes were identified in a Motif Search of 
the genome sequence databases of L. major, T. brucei 
and T. cruzi using the sequence motif H-[YFWH]-X2-
D-[VLI]-X2-[GA]-X3-[GSTA] (Sanger GeneDB). 
Candidates were then further selected using the 
additional criteria described in the Results. 
The Leishmania candidate, CDS - LmjF35.4990, was 
amplified from genomic DNA (14) using Pfu 
polymerase (Stratagene) and the primer pairs: 
5’LmIPCSBamHI (5’cgc gga tcc ATG ACG AGT 
CAC GTG ACA GC) and 3’LmIPCS*HindIII (ccc aag 
ctt TTA GTG CTC AGG CAA AGC CGC CG); and 
5’LmIPCSBamHI and 3’LmIPCSHindIII (ccc aag ctt 
GTG CTC AGG CAA AGC CGC CG). The products 
were cloned into the yeast and mammalian expression 
vectors pRS426MET25 and pcDNA3.1/Myc-HisA 
(Invitrogen), creating pRS426 LmIPCS and 
pcDNA3.1A LmIPCSMyc-His respectively. The S. 
cerevisiae AUR1 gene was similarly amplified from 
genomic DNA (Invitrogen) using the primer pair 
AURFXbaI (cat aga tct aga ATG GCA AAC CCT TT 
TTC GAG ATG G) and 3’ScIPCS*HindIII (ccc aag ctt 
TTA AGC CCT CTT TAC ACC TAG TGA CG), and 
the product cloned into pRS426MET25 to create 
pRS426 ScAUR1. Cloning sites are shown in lower 
case, with Leishmania and S. cerevisiae sequence in 
upper case. 
Construction of YPH499–HIS–GAL–AUR1 
auxotrophic S. cerevisiae strain - YPH499–HIS–GAL–
AUR1 S. cerevisiae strain was constructed in YPH499 
[Mat a; ura3-52; lys2-801amber; ade2-101ochre; trp1-
63; his3-200; leu2-1] (Stratagene) by bringing the 
expression of the yeast AUR1 gene under the control of 
the stringently regulated GAL1 promoter that is 
repressed in the presence of glucose (20). The AUR1 
promoter in the yeast genome was exchanged by a 
selection marker/promoter HIS/GAL1-cassette using 
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previously described methodology (21). The primer 
sequences for amplification of the HIS–GAL cassette 
were chosen as follows: (a) sequence for integration 
upstream of the coding region (nucleotides -200 to -
150) - AuriHISGalS 5’GGT AGT TGG TTA GTC 
CGA TCG CTC ACT TTT GGT TGT TGT TAA GTA 
CTT CAG GGC GAA TTG GAG CTC CAC3’; (b) 
sequence for integration at the initiation codon 
(nucleotides +1 to +50) - AuriHISGalAS 5’CAG TTT 
GGA GGT CTC TCT GAT AGA AAC CAT CTC 
GAA AAA GGG TTT GCC ATG GGG ATC CAC 
TAG TTC TAG3’. The numbers indicate the 
nucleotide positions in the S. cerevisiae DNA 
sequence, with the adenosine of the ATG initiation 
codon being defined as position +1. The 19 bp 
sequences at the 3′ ends of these oligonucleotides that 
are homologous to the sequences of the vector 
pGAL/HIS3 (22) and serve as a template for 
amplification of the GAL1/HIS3-cassette are 
underlined. Transformation into the haploid YPH499 
strain, selection on minimal medium lacking histidine 
but containing galactose and confirmation of the 
insertion of the HIS–GAL fragment were performed as 
previously described (23). YPH499–HIS–GAL–AUR1 
was maintained in SGR medium (4% galactose, 2% 
raffinose, 0.17% Bacto yeast nitrogen base, 0.5% 
ammonium sulphate) with galactose/raffinose rather 
than non-permissive dextrose as the carbohydrate 
source. For rapid cultivation of the mutant, YPGR 
medium (4% galactose, 2% raffinose, 1% yeast extract, 
2% peptone) was routinely used. 
Identification of Leishmania AUR1 orthologue – The 
YPH499–HIS–GAL–AUR1 S. cerevisiae strain was 
transformed with pRS426 ScAUR1 or pRS426 
LmIPCS and functionally complemented transformants 
selected on non-permissive SD medium (0.17% Bacto 
yeast nitrogen base, 0.5% ammonium sulphate and 2% 
dextrose) containing the nutritional supplements 
necessary to allow selection of transformants. 
Sequence analyses – Based on primary sequence, 
orthologues of LmIPCS (CDS - LmjF35.4990) were 
found by BLAST search of the T. brucei and T. cruzi 
databases (Sanger GeneDB) using WU-BLASTp 
(Gish, W. (1996-2001) http://blast.wustl.edu). 
Sequence alignments were made using CLUSTALW 
(24). Phylogenetic analyses were performed on the 
edited alignments using maximum parsimony 
(Protpars, Felsenstein, J. 1993. PHYLIP (Phylogeny 
Inference Package version 3.5c); distributed by the 
author, Department of Genetics, University of 
Washington, Seattle, USA). Topology predictions were 
performing using the PHD package (25). 
Expression of LmIPCS in a mammalian cell line - 
Human ARF1 was amplified from lymph node cDNA 
(Clontech) using the primers hARF1F (5'CCT GTC 
CAC AAG CAT GGG GAA CAT3' and hARF1R, 
5'CCT TCT GGT TCC GGA GCT GAT TGG3'.  The 
fragment was cloned into pcDNA3.1/CT-GFP-TOPO 
(Invitrogen) to produce the construct pcDNA3.1 
hARF1GFP. 
 The cell line HEK293 was grown in Dulbecco's 
modified eagle medium (DMEM), containing 10% 
FCS, 100 U/ml penicillin and 100 U/ml streptomycin at 
37°C in a humidified atmosphere with 5% CO2. 
 For transient transfection, cells were seeded in 6-
well plates +/- glass coverslips at a cell density of 2 x 
105 cells per well, and allowed to grow for 24 hours. 
Cells were then transfected with pcDNA3.1A 
LmIPCSMyc-His, pcDNA3.1 hARF1GFP, 
pcDNA3.1/Myc/His/lacZ or pcDNA3.1A vector alone, 
using Fugene 6 Transfection Reagent (Roche).  For 
each well, 3 µl of Fugene reagent was combined with 2 
µg of plasmid DNA.  For co-transfections, 6 µl of 
Fugene was used per well, with 2 µg of each construct. 
Immunofluorescence - 36 hours post-transfection 
HEK293cells were fixed with 4% paraformaldehyde 
(w/v) for 45 minutes at RT.  Expressed LmIPCS was 
detected by indirect immunofluorescence. Cells were 
washed in PBS, permeabilised in 0.5% Triton X-
100/PBS (v/v) for 10 mins and then blocked in 10% 
FCS/PBS (v/v) for 1 hour. Samples were incubated 
with rabbit polyclonal anti-myc (Abcam, 1:200 
dilution) in blocking solution for 1 hour. After washing 
in PBS, cells were incubated in Alexa Fluor 633 goat 
anti-rabbit IgG (Invitrogen, 1:250) in blocking solution 
for 1 hour. After washing in PBS, coverslips were 
mounted on slides using Vectashield with DAPI 
(Vector Laboratories, UK). Samples were visualized by 
confocal microscopy using a Zeiss LSM 510 meta with 
a Plan-Apochromat 63x/1.4 Oil DIC I objective lens.  
Images were acquired using LSM 510 version 3.2 
software (Zeiss).  
Metabolic labelling and analyses - HEK293 cells, 36 
hours post-transfection, were labelled for 16 hours in 
DMEM supplemented with 10% foetal calf serum and 
20 µCi/ml of myo-[3H] inositol (102 Ci/mmol) 
(Amersham). These cells were also labelled with NBD 
C6 –ceramide complexed with BSA (Molecular Probes) 
for 1 hour at 37°C in serum-free media as previously 
described (26). L. major (MHOM/IL/81/Friedlin; FV1 
strain) maintained as previously described (14) were 
similarly labelled with NBD ceramide but at 26°C for 2 
hours. Lipids were extracted and analysed as 
previously described (27,28), although the NBD 
ceramide labelled samples were, following 
fractionation by thin layer chromatography, scanned 
using a FLA3000 (Fuji).  
 Logarithmic phase yeast (unless stated otherwise) 
were harvested and incubated at 10 OD600/ml in 0.25 
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ml inositol-free SD medium at 30°C for 20 minutes. 10 
µCi [3H]inositol were added and the cells incubated for 
40 minutes. 0.75 ml of fresh medium was added and 
the incubation continued for 80 minutes. Yeast were 
also labelled with C6 –ceramide complexed with BSA 
as previously described (29). Cells were harvested by 
centrifugation and washed twice with 1 M sorbitol. 
Chloroform/methanol (0.4 ml; 1:1 v/v) was added and 
cells were disintegrated with glass beads. The pellet 
was re-extracted several times with 
chloroform/methanol/water (10:10:3, per vol.), the 
combined supernatants dried and the lipids prepared 
and analysed as previously described (27,28). Again 
NBD ceramide labelled samples were imaged using a 
FLA3000 (Fuji). 
Agar diffusion assay – Wild type YPH499 yeast and 
the transgenic strain YPH499–HIS–GAL–AUR1 
complemented with ScAUR1 or LmIPCS were assayed 
for susceptibility to Aureobasidin A (Takara), myriocin 
(Sigma) and cycloheximide (Sigma) as previously 
described (30). Briefly, 2.4x107 logarithmically 
dividing cells were embedded in 15 ml of YPD agarose 
(2% dextrose, 1% yeast extract, 2% peptone, 0.8% 
agarose) on 100mm2 square Petri dishes (Sarstedt). 
Inhibitors were applied in DMSO at the concentrations 
described below and the dishes incubated at 30°C. 
 
RESULTS 
 
Functional cloning of the Leishmania AUR1 
orthologue- 
 Candidate genes encoding the putative protozoan 
protein were selected using a bioinformatic approach 
based on that used in the identification of the metazoan 
enzyme sphingomyelin (SM) synthase (29). Briefly, a 
conserved motif shared by the lipid phosphate 
phosphatase (LPP) family, fungal AUR1p proteins and 
animal sphingolipid synthases (H-[YFWH]-X2-D-
[VLI]-X2-[GA]-X3-[GSTA]) was used to screen the 
genome sequence databases of the kinetoplastids 
(www.genedb.org/). Of the 8 candidates identified, one 
was of unknown function, had sequence orthologues in 
both Trypanosoma and Leishmania spp., had 
transmembrane domains (TMDs) consistent with a 
Golgi localised IPC synthase and had no orthologue in 
mammalian cells (which do not possess an IPC 
activity). The gene encoding this putative protozoan 
IPC synthase is present as a single copy in L. major. In 
contrast, the trypanosomes possess multiple non-
identical loci, 2 in T. cruzi, and 4 in T. brucei. The 
Leishmania candidate was amplified and cloned into a 
URA3 selectable yeast expression vector to create 
pRS426 LmIPCS. In the auxotrophic yeast strain 
YPH499-HIS-GAL-AUR1 (see Experimental 
Procedures), the essential AUR1 gene, believed to 
encode at least part of an IPC synthase (31), is under 
the control of the GAL1 promoter and so is repressed in 
the presence of glucose. In non-permissive glucose-
containing SD media, transformation with pRS426 
LmIPCS restored the growth of YPH499-HIS-GAL-
AUR1, as did the ectopic expression of S. cerevisiae 
AUR1p (ScAUR1) (figure 2A). The wild type 
(YPH499) cannot grow without uracil.  
 Biochemical analysis of the YPH499-HIS-GAL-
AUR1 strain showed that suppression of AUR1 
expression by incubation in non-permissive SD media 
leads to significantly reduced incorporation of tritiated 
inositol into base-resistant lipid species. This strongly 
suggests that IPC synthase activity is down-regulated 
under these conditions (figure 2B). The auxotrophic 
mutant strain transformed with empty pRS426MET25 
vector was grown for 20 hours in either SD or 
permissive SGR media. At this point, both sets of cells 
were in the stationary phase of growth and 100% viable 
(as shown by a trypan blue exclusion assay and plating 
on permissive media; data not shown). Furthermore 
when grown in non-permissive media YPH499-HIS-
GAL-AUR1 demonstrated cell clumping (data not 
shown) perhaps mirroring the pleomorphic defects in 
cell morphology and division previously observed in 
AUR1 mutants of S. cerevisiae and S. pombe (31,32). 
Analysis of the complemented YPH499-HIS-GAL-
AUR1 line confirmed LmIPCS as a functional 
orthologue of AUR1p. YPH499-HIS-GAL-AUR1 
rescued using either pRS426 ScAUR1 or pRS426 
LmIPCS and labelled with [3H]-inositol demonstrated a 
base-resistant sphingolipid profile identical to that 
observed in the wild type (figure 2B). However, in the 
LmIPCS complemented line the relative quantity of 
labelled mannose inositol phosphorylceramide (MIPC) 
was significantly diminished. In addition, an 
accumulation of base-sensitive lyso-PI and lipid X was 
evident (figure 2B). A yeast mutant deficient in 
ceramide synthesis, with a consequently low level of 
IPC synthase activity, exhibits a similar phenotype 
(33), suggesting that LmIPCS does not function 
optimally in this system. This conclusion is supported 
by the relatively slow growth of the LmIPCS 
complemented yeast (data not shown). Despite this 
phenotype, these complementation data establish 
LmIPCS as a functional orthologue of S. cerevisiae 
AUR1p, the putative IPC synthase. 
The Leishmania AUR1 orthologue defines a new class 
of sphingolipid synthase – Based on primary sequence 
identity, orthologues of LmIPCS were identified in the 
related kinetoplastids, T. cruzi and T. brucei (see 
Experimental Procedures), suggesting that IPC 
synthase is a ubiquitous feature of this important group 
of flagellated parasites. Like Leishmania spp., T. cruzi 
synthesizes IPC as its predominant complex 
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sphingolipid and this parasite is known to possess IPC 
synthase activity (17). Therefore the 2 closely related 
T. cruzi predicted proteins, sharing 52-53% sequence 
identity and 69-70% similarity with the Leishmania 
orthologue, were provisionally designated TcIPCS1 
and TcIPCS2. There are no published data indicating 
whether T. brucei produces IPC or SM. Given this 
uncertainty, the 4 predicted orthologues were 
provisionally designated as T. brucei sphingolipid 
synthase (TbSLS) 1-4. The 4 TbSLS predicted proteins 
share 43-44% identity and 61-63% similarity with 
LmIPCS. The high level of conservation within these 
kinetoplastid species is illustrated in figure 3A, 
together with the 7 TMDs identified during topology 
prediction of LmIPCS and those regions largely 
conserved with respect to the animal SM synthases 
(29). SM synthase motifs D3 (C-G-D-X3-S-G-H-T) and 
D4 (H-Y-T-X-D-V-X3-Y-X6-F-X2-Y-H) are similar to 
the C2 and C3 motifs in LPP (29), as are domains 3 
and 4 of the fungal AUR1p (34). These regions contain 
the histidine and aspartate residues (underlined) that 
comprise the catalytic triad that mediates nucleophilic 
attack on lipid phosphate ester bonds (29,35). 
Mutagenesis of this triad has been shown to inactivate 
fungal IPC synthase activity (36). Huitema et al  
(2004) predict that the D1 (P-L-P-D) and D2 (R-R-X8-
Y-X2-R-X6-T) motifs are entirely unique to the SM 
synthases.   
 Analysing the conserved domains D1, D3 and D4 
in isolation (figure 3B), it is clear that the predicted 
kinetoplastid proteins possess the histidine and 
aspartate residues forming the catalytic triad. However, 
it is also evident that they demonstrate a higher degree 
of similarity in these regions with the animal SM 
synthases than with the fungal AUR1p proteins. This is 
clearly illustrated in the 100% identity of D1, 
positioned between the first two TMDs of both the 
animal and kinetoplastid proteins, a domain with no 
equivalent in the fungal enzyme. Notably, both 
mammal (29) and Leishmania (37) sphingolipid 
synthases utilise ceramide (rather than phytoceramide 
as in fungi) so perhaps the conserved D1 domain 
functions in the preferential binding of this substrate. 
Unlike the SM synthases (29) the protozoan D1 is 
predicted to face the cytosol (figure 4D). However, 
there is no experimental evidence to support this 
prediction and, furthermore, ceramide is delivered to 
both the lumenal and cytosolic faces of the Golgi 
apparatus (38). Conversely, the protozoan proteins do 
not possess a motif with similarity to SM synthase D2.  
 These data indicate that the protozoan enzymes are 
not closely related to fungal AUR1p proteins, despite 
exhibiting an equivalent function at least in the case of 
Leishmania. Further, phylogenetic analysis of both 
predicted SM and IPC synthase sequences using 
maximum parsimony demonstrated that the 
kinetoplastid proteins form a distinct clade and as such 
are proposed to define a new class of sphingolipid 
synthases (figure 3C). This analysis failed to place the 
putative SM synthases of the malaria parasite, 
Plasmodium falciparum (PfSMS) (29), raising a 
question over their classification and evolutionary 
origin. 
Functional analyses of LmIPCS activity in a 
mammalian cell line – As described above, mammalian 
cells do not possess either IPC synthase or IPC (figure 
1). In order to assay the activity of LmIPCS in a 
mammalian system, an epitope-tagged gene copy was 
ectopically expressed in HEK293 cells and the cells 
subsequently labelled with [3H]-inositol to screen for 
the synthesis of inositol-containing lipids or NBD-
ceramide for the analysis of sphingolipid synthesis. 
Fractionation of inositol labelled lipids by thin-layer 
chromatography demonstrate the presence of a base-
resistant inositol-containing lipid co-migrating with 
Leishmania IPC (figure 4A). The negative control, 
HEK293 cells transfected with lacZ, do not synthesize 
this lipid species. Leishmania spp. IPC predominantly 
contains C16 and C18 sphinganine and fatty acid 
moieties (37,39,40), more similar to the sphingomyelin 
in mammalian cells (41) than the very long chain fatty 
acid group predominant in S. cerevisiae IPC species 
(42). Additional analysis of NBD ceramide labelled 
cells demonstrated that expression of LmIPCS in the 
mammalian cell line leads to production of a ceramide-
containing species that co-migrates with both -
Leishmania and yeast IPC (figure 4B). These results 
strongly indicate that the Leishmania LmIPCS gene 
encodes a protein that can constitute IPC synthase 
activity in a null background. 
 AUR1p has been localised to the Golgi apparatus 
in S. cerevisiae (36), whilst in mammalian cells the 2 
distinct isoforms of SM synthase have been localised to 
the Golgi and the plasma membrane (29). Immuno-
localisation of epitope-tagged LmIPCS in HEK293 
cells demonstrated that the protozoan enzyme is 
concentrated within the Golgi apparatus as identified 
by the co-localisation of a GFP-tagged marker, ARF 1 
(figure 4C).  In addition, minor quantities of the protein 
also localise to the plasma membrane when the 
expression levels are high (figure 4C). Topology 
prediction using the PHD package indicates that the 
residues predicted to form the LmIPCS catalytic triad 
are orientated towards the Golgi lumen (or the cell 
surface) in a conformation identical to that predicted 
for both fungal AUR1p and animal SM synthases 
(29,36) (figure 4D). These observations suggest that, as 
in animals and fungi, kinetoplastid sphingolipid 
synthesis takes place in the lumen of the Golgi. 
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Specific inhibition of Leishmania IPC synthase - The 
expression of functional protozoan orthologues in the 
mutant yeast system described (figure 2) provided an 
ex vivo system in which to screen the existing fungal 
IPC synthase inhibitors against the functional 
Leishmania orthologue. In this study, the diffusion 
assay system previously described, with the 
sphingolipid bypass mutant (AGD) as a negative 
control, was utilised (11,30). The conditional AUR1 
mutant strain rescued with ScAUR1 was, like the wild 
type control, sensitive to cycloheximide (an inhibitor of 
protein translation), myriocin (an inhibitor of serine 
palmitoyltransferase, SPT, which mediates the first 
step in sphingolipid biosynthesis) and Aureobasidin A 
(an inhibitor of fungal IPC synthase (11), to which 
mutations in AUR1 confer resistance (10)). The mutant 
rescued with LmIPCS, while sensitive to 
cycloheximide and myriocin, was resistant to 
Aureobasidin A at 25µM (figure 5A). However, by 
increasing the concentration of the IPC synthase 
inhibitor 4 fold (to 100µM) sensitivity of LmIPCS to 
the drug was detected (figure 5B). The sphingolipid 
bypass strain AGD is able to grow without 
synthesizing sphingolipids and so is able to tolerate 
loss-of-function mutations in both SPT and IPC 
synthase (11). Therefore AGD is resistant to anti-
fungals targeting either of these enzymes, provided 
these agents have a specific mode of action (30). The 
lack of an inhibitory effect of Aureobasidin A at 
100µM on the growth of AGD, together with its action 
against the rescued mutant, demonstrates that the drug 
specifically inhibits LmIPCS as well as ScAUR1p. The 
LmIPCS rescued mutant showed increased sensitivity 
to myriocin (an inhibitor of SPT) when compared with 
either the wild-type or the mutant rescued with 
ScAUR1 (figure 5A). The reason for this is unclear, but 
this observation correlates with the generally fragile 
nature of the cells complemented with the protozoan 
orthologue that results in a reduced rate of growth (data 
not shown). 
 Aureobasidin A (at 20µM) also exhibited an 
inhibitory effect against insect stage L. major in cell 
culture. However, in this system, the inhibitor was non-
specific as demonstrated by an equivalent activity 
against parasites without an active sphingolipid 
biosynthetic pathway (14) in which LmIPCS would be 
predicted to be redundant (data not shown). 
  
DISCUSSION 
 
Sphingolipids are essential membrane components of 
eukaryotic cells. In mammalian systems, the major 
complex sphingolipid is sphingomyelin, whilst in the 
kinetoplastids, including Leishmania spp., it is inositol 
phosphorylceramide (IPC) (7). A similar situation 
exists in fungi where IPC is synthesized utilising the 
enzyme IPC synthase. The fungal IPC synthases are 
believed to be encoded by the AUR1 gene which has 
been demonstrated to be essential for viability (32,42). 
No close relatives of this gene can be identified in the 
kinetoplastid genome databases. However, in the study 
reported here, we have identified the single copy gene 
encoding the functional AUR1 orthologue from 
Leishmania major (LmIPCS), utilising a combination 
of bioinformatic and functional genetic methods. The 
protein encoded by this gene shares only limited amino 
acid sequence identity with fungal AUR1p but has 
closely related sequence orthologues in both the 
African and American Trypanosomes. Notably, the 
predicted kinetoplastid AUR1p orthologues 
demonstrate significant homology to 3 of the 4 
conserved domains of the recently identified animal 
sphingomyelin (SM) synthases (29). This indicates 
that, despite possessing an equivalent function, the 
protozoan enzymes are not closely related to the fungal 
IPC synthases (AUR1p) but share more similarity, at 
least at a primary sequence level, with the animal SM 
synthases. Indeed, phylogenetic analyses indicated that 
the kinetoplastid proteins define a new class of 
sphingolipid synthases clustering with neither the 
fungal or animal sequences (figure 3C). The 
significance of this observation in evolutionary terms is 
unclear, although the identification of a plant IPC 
synthase will facilitate more informative analyses.  
 In addition to complementing an auxotrophic 
AUR1 yeast mutant, expression of LmIPCS in a 
mammalian cell line (null for IPC and IPC synthase 
activity) led to the synthesis of inositol and ceramide 
labelled lipids that co-migrated with Leishmania and 
yeast IPC. This strongly suggests that LmIPCS is able 
to constitute IPC synthase activity in an axenic system. 
LmIPCS is largely confined to the Golgi apparatus, as 
indicated by subcellular localisation, a situation similar 
to that for the proposed sphingolipid synthases of both 
fungi and animals (29,36). The association of LmIPCS 
with the Golgi membrane is predicted to be mediated 
by seven transmembrane helices, with the putative 
active site including the catalytic triad of histidine and 
aspartate residues orientated towards the lumen as in 
fungal AUR1p and mammalian sphingolipid synthase 
(29,36). Thus it is likely that the protozoan, 
mammalian and fungal enzymes possess a conserved 
mechanism of action similar to that described for LPPs 
(35) whereby, in the case of the yeast and 
kinetoplastids, IPC synthase catalyses the transfer of an 
inositol phosphate group from phosphatidylinositol to 
the 1-hydroxyl group of ceramide or phytoceramide 
releasing diacyl glycerol as a by-product. This is 
predicted to occur via a two-step process involving 
initial transfer of the inositol phosphate residue to an 
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activated histidine in the active site, with the phosphate 
intermediate being subsequently subjected to 
nucleophilic attack by the oxygen of the 
(phyto)ceramide hydroxyl group resulting in transfer to 
the sphingoid base. Notably, mutation of His-294, part 
of catalytic triad in the yeast AUR1p, results in non-
viable haploid cells (36). Taken together with the 
phylogenetic analysis in this study, the predicted 
conservation of the catalytic mechanism suggests that 
fungal, animal and protozoan sphingolipid synthases 
have evolved into 3 distinct classes from a common 
ancestor. Conversely, the soluble bacterial SM 
synthase lacks the motifs believed to be integral for 
activity of the eukaryotic enzymes (43) indicating that 
it arose independently.  
 The data presented here demonstrate that LmIPCS 
(like its fungal equivalent) is inhibited by Aureobasidin 
A. Given that IPC synthase activity is detectable in the 
pathogenic stages of all the parasitic kinetoplastids 
studied to date (15,17) the protozoan enzyme may 
represent a tractable drug target.  The toxicity and 
expense of available treatments for leishmaniasis, 
African sleeping sickness and Chagas’ disease remain a 
major international health problem. These facts, 
coupled with the prevalence of drug resistant parasites, 
make the discovery of novel drug targets a priority. 
The identification and characterization of the 
kinetoplastid AUR1 orthologue, a probable IPC 
synthase with no functional equivalent in mammalian 
cells, will raise the possibility of developing specific 
inhibitors with little or no mammalian toxicity. In 
addition, the close evolutionary relationship observed 
between the kinetoplastid AUR1p orthologues 
indicates that the development of broad-spectrum 
inhibitors is a feasible objective, work which may lead 
to a new generation of anti-protozoals directed against 
the causative agents of a range of emerging diseases. 
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Figure 1 
Schematic illustrating the dichotomy of complex sphingolipid biosynthesis: mammals (and other animals) producing 
sphingomyelin (SM) via SM synthase; and fungi, plants and kinetoplastids synthesizing inositol phosphorylceramide 
(IPC) utilising IPC synthase. Adapted from Denny and Smith, 2004 (44). 
 
Figure 2 
A. Rescue of YPH499–HIS–GAL–AUR1 by complementation with either the yeast AUR1 (ScAUR1) or a 
predicted Leishmania orthologue identified using bioinformatics (LmIPCS). YPH499 – wild type; pRS426 - 
YPH499–HIS–GAL–AUR1 pRS426MET25; ScAUR1 - YPH499–HIS–GAL–AUR1 pRS426 ScAUR1; 
LmIPCS - YPH499–HIS–GAL–AUR1 pRS426 LmIPCS. 
  SD – synthetic minimal media supplemented (or not) with histidine (HIS) and uracil (URA) for selection of the 
  pRS426MET25 plasmid.  
 
B. YPH499–HIS–GAL–AUR1 is deficient in inositol sphingolipid biosynthesis when incubated in non-
permissive, glucose-containing SD media, however complementation with either yeast AUR1 (ScAUR1) or the 
protozoan orthologue (LmIPCS) open reading frames facilitates synthesis of a base-resistant inositol 
sphingolipid profile identical to that of wild type yeast. Material extracted from wild type YPH499, IPT1 
mutant RCD113 (45) and YPH499–HIS–GAL–AUR1 transformed with pRS426MET25, pRS426 ScAUR1 or 
pRS426 LmIPCS, maintained in media indicated and inositol labelled as described in Experimental 
Procedures. The base resistant lipids (BASE +, indicated left) which co-migrated with base sensitive PI species 
(BASE -, indicated right) are designated as IPC and are likely to represent species with varying levels of 
hydroxylation of the sphinganine and fatty acid moieties (7,46). Unlike the other samples YPH499–HIS–GAL–
AUR1 pRS426 was labelled, in both permissive (SGR) and non-permissive (SD) media, when at the stationary 
phase of growth. It is likely that this accounts for the minor differences in the labelled profile. The identities of 
the base resistant sphingolipid species (indicated left) were established by comparison with the S. cerevisiae 
IPT1 mutant strain RCD113 which is deficient in M(IP)2C synthesis and accumulates MIPC (45).  
 IPC – inositol phosphorylceramide; MIPC – mannose inositol phosphorylceramide; M(IP)2C – mannose 
(inositol phosphorus)2 ceramide; PI – phosphatidylinositol; X – unknown; O – origin; SD – synthetic minimal 
media with glucose; SGR – synthetic minimal media with galactose. 
 
Figure 3 
A. The predicted kinetoplastid AUR1p orthologues are highly conserved. CLUSTALW alignment. TM – 
predicted LmIPCS transmembranes domains; D – conserved SM synthase domains. Shaded black – 100% 
identical; shaded grey – 100% similarity.  
B. The predicted kinetoplastid proteins share a high level of similarity with the SM synthases with respect to 3 
domains. Edited CLUSTALW alignments of the conserved SM synthase domains D1, D3 and D4. Equivalent 
to LmIPCS amino acids 67-70, 212-221 and 264-284 respectively. Shaded black – 50% identical; shaded grey 
– 50% similarity. * - conserved histidine and aspartate residues that form the catalytic triad. 
C. The kinetoplastid proteins define a new class of sphingolipid synthases. An evolutionary tree constructed using 
maximum parasimony of sequence equivalent to LmIPCS amino acids 77-313, a region conserved between the 
Metazoa, Fungi, Apicomplexa and Kinetoplastidae and including the domains within which the amino acids 
forming the catalytic triad are present. The sequence of the human lipid phosphate phosphatase 1 (LPP1) was 
the designated outgroup. Bootstrap scores >60 indicated. 
 
T. brucei SLS1-4 accession numbers: Tb09.211.1020, Tb09.211.1000, Tb09.211.1030, Tb09.211.1010; T. cruzi 
IPCS1&2: Tc00.1047053506885.124, Tc00.1047053510729.290; L. major IPCS: LmjF35.4990; Aspergillus fumigatus 
AUR1p: AAD22750; Candida albicans AUR1p: AAB67233; Pneumocystis carinii AUR1p: CAH17867; 
Saccharomyces cerevisiae AUR1p: NP_012922; Schizosaccharomyces pombe AUR1p: Q10142; Plasmodium 
falciparum SMS 1&2: MAL6P1.178, MAL6P1.177; Caenorhabditis elegans SMS1-3: Q9U3D4, AAA82341, 
AAK84597; Homo sapiens SMS1&2: AB154421, Q8NHU3; Mus musculus SMS1&2: Q8VCQ6, Q9D4B1; Homo 
sapiens LPP1 (outgroup): O14494. 
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Figure 4 
A. LmIPCS activity in mammalian HEK293 cells. HEK293 transiently expressing LmIPCS from pcDNA3.1 
synthesized a base resistant, inositol-labelled lipid species (σ) that co-migrated with L. major inositol 
phosphorylceramide. This lipid was absent in cells treated identically but expressing lacZ only. Following base 
treatment (BASE +) both lines demonstrated inositol-labelled lipid species without equivalents in untreated 
cells (*). These were assumed to be breakdown products of base sensitive (BASE -) inositol lipid species. O – 
origin; PI – L. major phosphatidylinositol; IPC – L. major inositol phosphorylceramide; PIP – L. major 
phosphatidylinositol phosphate. 
B. LmIPCS activity in mammalian HEK293 cells. HEK293 cells expressing LmIPCS incorporated NBD 
ceramide into a novel lipid species (sample 4) absent in control cells expressing lacZ (sample 5). This 
sphingolipid co-migrated with NBD labelled IPC from both S. cerevisiae (sample 2) and L. major (sample 3) 
as demonstrated by fractionation of the mammalian together with either the yeast or protozoan material 
(samples 2+4 and 3+4 respectively). 1 – NBD ceramide; 2 – S. cerevisiae YPH499; 3 – L. major; 4- HEK293 
pCDNA3.1 LmIPCS; 5 – HEK293 pCDNA3 lacZ; O – origin; SM – NBD labelled sphingomyelin inferred 
from relative mobility with respect to IPC (29); IPC – NBD labelled inositol phosphorylceramide; CER – NBD 
ceramide. 
C. LmIPCS localises to the Golgi apparatus in mammalian HEK293 cells. i) DAPI stained; ii) Human ARF1-
GFP; iii) LmIPCS; iv) merge of i-iii. 
D. The catalytic triad of amino acids is orientated towards the Golgi lumen. Predicted membrane topology of 
LmIPCS. 
 
Figure 5 
LmIPCS is specifically susceptible to the fungal inhibitor Aureobasidin A. Agar diffusion assay. 
 
A. Volumes of 1, 2 and 3 µl of 25µM Aureobasidin A (AbA), 1mM myriocin (MYR), 25µM cycloheximide 
(CYC) and DMSO as a control (CTL) spotted onto yeast plates prepared as described in Experimental 
Procedures.  
B. Volumes of 1, 2 and 3 µl of 100µM Aureobasidin A spotted onto yeast plates prepared as described in 
Experimental Procedures. 
  
YPH499 – wild type yeast; ScAUR1 - YPH499–HIS–GAL–AUR1 pRS426 ScAUR1; LmIPCS - YPH499–HIS–GAL–
AUR1 pRS426 LmIPCS; AGD – yeast sphingolipid bypass mutant, negative control. 
 
 







